Skip to content

Neurology Measures in FA Children

Neurological Measures of Progression in Children With Friedrich Ataxia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03418740
Enrollment
108
Registered
2018-02-01
Start date
2017-11-20
Completion date
2023-02-02
Last updated
2025-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Friedreich Ataxia

Keywords

Friedreich, Ataxia, FRDA, FA, Friedrich Ataxia (FRDA)

Brief summary

The purpose of this study is to identify ways to follow progression of Friedreich's Ataxia (FA) and be able to measure changes over time in children with FA. Participants will have biannual visits to observe how the disease progresses over time and determine the rate of progression. Funding Source- Food and Drug Administration Office of Orphan Products Development (FDA OOPD).

Detailed description

Investigators seek to identify biological and clinical tests to be used in future clinical trials. The purpose of this research study is to learn more about Friedreich's Ataxia (FA) progression in children. There will be biannual visits which will include a core set of tests and procedures. These include: a collection of medical history, detailed neurological exam, ataxia scales, and health questionnaires. At each visit, blood and cheek swab samples will be obtained to monitor frataxin levels. A select number of Children's Hospital of Philadelphia (CHOP) participants will have the opportunity to participate in further procedures to better understand how FA affects different tissues. These include a Magnetic Resonance Imaging (MRI) scan and a Motor Evoked Potentials (MEP) procedure. The MRI scan analyzes how muscle activity is affected in FA. The magnet will be used to capture images of the calf muscle before and after exercising on an ergonomic foot pedal. The MEP procedure measures how strong the connection is between the brain's motor cortex and a selected body part, specifically the participant's dominant hand.

Interventions

None listed

Sponsors

University of Florida
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
Food and Drug Administration (FDA)
CollaboratorFED
Friedreich's Ataxia Research Alliance
CollaboratorOTHER
Children's Hospital of Philadelphia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Males or females age 2 to 18 years. 2. Genetically confirmed diagnosis of Friedreich's Ataxia (FA) or clinically confirmed diagnosis of FA, pending confirmatory genetic testing through a commercial or research laboratory 3. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion criteria

1\) Inability to complete study evaluations

Design outcomes

Primary

MeasureTime frameDescription
Change in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreBaseline up to 36 MonthsThe Friedreich Ataxia Rating Scale (FARS) measures neurological function in FA. It is a composite measure reflecting neural substrates with five-subscales (sections A to E), measuring bulbar function, upper limb coordination, lower limb coordination, peripheral nerves, and upright stability. The modified FARS (mFARS) shortens the bulbar subscale to 2 items and excludes the peripheral nerve subscale. Total scoring is a summation of subscales, with a maximum score of 93 points for mFARS and 125 for FARS. The mFARS score ranges for each subscale are: Bulbar: 0 - 5, Upper Limb: 0 - 36, Lower Limb: 0 - 16, Upright Stability: 0 - 36. The overall change in mFARS and its sub scores across 3 years was the outcome measure analyzed at 0, 1, 2, and 3 year visits. Each subsection has a minimum score of 0, indicating minimal effect for that component. Maximum values per section vary based on the tasks performed in each subsection; a higher score indicates greater dysfunction on that component.

Secondary

MeasureTime frameDescription
Change in 9-Hole Peg Test (9HPT)Baseline up to 36 MonthsThis test examines finger dexterity and involves placing and removing nine pegs in a pegboard and then removing them in the quickest possible time. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The 9HPT was analyzed at 0, 1, 2, and 3 year visits.
Change in Timed Up and Go (TUG) TestBaseline up to 36 MonthsThe Timed Up and Go (TUG) test is a timed measure during which the participant has to stand up from a chair, walk 3 meters, turn around, walk back, and sit down. The participant is asked to perform the task as fast and as safe as possible. The TUG is a norm-referenced measure that has established reliability for quickly assessing functional ambulatory mobility and dynamic balance in adults and children. The TUG test was analyzed at 0, 1, 2, and 3 year visits.
Change in Timed 25-Foot Walk (T25FW) TestBaseline up to 36 MonthsThe timed 25-foot walk (T25FW) test examines gait speed. The participant walks the distance of 25 feet as fast and safe as possible. Participants may use assistive devices during this task. The T25FW test was analyzed at 0, 1, 2, and 3 year visits.
Change in FA-Activities of Daily Living Scale (ADL) ScoreBaseline up to 36 MonthsThe Activities of Daily Living (ADL) assesses functional status as a measurement of the participant's ability to perform activities of daily living independently. The ADL comprises 9 questions, each question scored on a scale of 0 to 4, though participants may use increments of 0.5 if they feel they fall between two items. As with the mFARS, the total ADL score is comprised of a summation of each scored question. A minimum value of 0 on the ADL scale indicates self-evaluation of minimal effect for neurological disease components. A maximum score of 36 on the ADL indicates most severe self-evaluation of symptoms included on the survey. The overall change in ADL score across 3 years was analyzed at 0, 1, 2, and 3 year visits.
Change in 1-minute Walk (1MW) and 6-minute Walk (6MW) TestsBaseline up to 36 MonthsThe Timed 1-minute Walk (T1MW) and timed 6-minute Walk are quantitative mobility and leg function performance tests based on distance traveled in one minute and six minutes. The participant is directed to one end of a clearly marked course and is instructed to walk back and forth as quickly as possible for one minute. The task is then repeated for six minutes. The distance is calculated by measuring how far the participant travels along the marked course.
Change in Berg Balance Scale (Full Length) (BBS) ScoreBaseline up to 36 MonthsThe Berg Balance Scale (BBS) is a widely used assessment to determine a person's balance abilities. The BBS includes a 14-item scale with static and dynamic activities of varying difficulty. The overall change in BBS score across 3 years was analyzed at 0, 1, 2, and 3 year visits. Scoring is based on a summation of the 14 item tasks scored on a five-point scale, with a range of 0-4 for each task. 0 = lowest level of function 4 = highest level of function. Highest possible score = 56 A score of \< 45 indicates a greater risk of falling.

Countries

United States

Participant flow

Pre-assignment details

Overall, among 108 individuals enrolled, 19 were excluded from the analysis population for one or more reasons. These included missing mFARS data at baseline or follow-up, early disease stage, and inability to ambulate at baseline.

Participants by arm

ArmCount
FACHILD
The population enrolled in this study was a young, severely affected cohort, indicated by high GAA1 repeat lengths and early ages of onset. It was a mixed early/typical FRDA population, suggesting a certain level of diversity despite tight pediatric enrollment criteria.
89
Total89

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up13
Overall StudyScheduling Issues7
Overall StudyUnable to Continue Consent1
Overall StudyWithdrawal by Subject2

Baseline characteristics

CharacteristicFACHILD
Age, Continuous13.3 Years
STANDARD_DEVIATION 2.8
Bulbar Function (FARS A, 5)0.3 units on a scale
STANDARD_DEVIATION 0.5
Lower Limbs (FARS C, 16)5.9 units on a scale
STANDARD_DEVIATION 2.4
mFARS Total (93)37.8 units on a scale
STANDARD_DEVIATION 11.7
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
89 participants
Sex: Female, Male
Female
48 Participants
Sex: Female, Male
Male
41 Participants
Upper Limbs (FARS B, 36)9.2 units on a scale
STANDARD_DEVIATION 5.3
Upright Stability (FARS E, 36)22.3 units on a scale
STANDARD_DEVIATION 5.3

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
1 / 89
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Change in mFARS (Modified Friedreich's Ataxia Rating Scale) Score

The Friedreich Ataxia Rating Scale (FARS) measures neurological function in FA. It is a composite measure reflecting neural substrates with five-subscales (sections A to E), measuring bulbar function, upper limb coordination, lower limb coordination, peripheral nerves, and upright stability. The modified FARS (mFARS) shortens the bulbar subscale to 2 items and excludes the peripheral nerve subscale. Total scoring is a summation of subscales, with a maximum score of 93 points for mFARS and 125 for FARS. The mFARS score ranges for each subscale are: Bulbar: 0 - 5, Upper Limb: 0 - 36, Lower Limb: 0 - 16, Upright Stability: 0 - 36. The overall change in mFARS and its sub scores across 3 years was the outcome measure analyzed at 0, 1, 2, and 3 year visits. Each subsection has a minimum score of 0, indicating minimal effect for that component. Maximum values per section vary based on the tasks performed in each subsection; a higher score indicates greater dysfunction on that component.

Time frame: Baseline up to 36 Months

Population: Among 108 individuals enrolled,19 were excluded from the analysis population for one or more concurrent reasons. These included missing mFARS data (baseline or follow-up, n = 6), early disease stage (n = 3, mFARS baseline values 1, 7, 12.3), and inability to ambulate at baseline (n = 13).

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoremFARS 1Y2.9 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoremFARS 2Y4.9 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoremFARS 3Y7.7 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS E 1Y2.2 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS E 2Y3.7 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS E 3Y5.5 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS B 1Y0.3 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS B 2Y0.3 units on a scale
FA ChildrenChange in mFARS (Modified Friedreich's Ataxia Rating Scale) ScoreFARS B 3Y0.6 units on a scale
Secondary

Change in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests

The Timed 1-minute Walk (T1MW) and timed 6-minute Walk are quantitative mobility and leg function performance tests based on distance traveled in one minute and six minutes. The participant is directed to one end of a clearly marked course and is instructed to walk back and forth as quickly as possible for one minute. The task is then repeated for six minutes. The distance is calculated by measuring how far the participant travels along the marked course.

Time frame: Baseline up to 36 Months

Population: Walking tests were carried out in the order: T25FW (twice), 1MW (twice), 6MW, and TUG. There was a notable increase in fatigue and refusals to complete the longer walking tests after the first trial of the 1MW, followed by the 6MW. As the difficulty of the tests increased the amount of missing data increased, consistent with the progressive nature of FRDA. Possible reasons for not performing a test were collected as fatigue, refused, unable and unable, unrelated to disease progression.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests1MW 1Y-11 meters
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests1MW 2Y-15.7 meters
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests1MW 3Y-23.1 meters
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests6MW 1Y-13.1 meters
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests6MW 2Y-65.8 meters
FA ChildrenChange in 1-minute Walk (1MW) and 6-minute Walk (6MW) Tests6MW 3Y-67.4 meters
Secondary

Change in 9-Hole Peg Test (9HPT)

This test examines finger dexterity and involves placing and removing nine pegs in a pegboard and then removing them in the quickest possible time. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The 9HPT was analyzed at 0, 1, 2, and 3 year visits.

Time frame: Baseline up to 36 Months

Population: The number of participants analyzed decreased after baseline at years 1, 2, and 3 as subjects were unable to complete the test. Reasons for not performing a test were missed visits or refusal to complete task.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in 9-Hole Peg Test (9HPT)9HPT 1Y-0.1 seconds
FA ChildrenChange in 9-Hole Peg Test (9HPT)9HPT 2Y-0.2 seconds
FA ChildrenChange in 9-Hole Peg Test (9HPT)9HPT 3Y-0.3 seconds
Secondary

Change in Berg Balance Scale (Full Length) (BBS) Score

The Berg Balance Scale (BBS) is a widely used assessment to determine a person's balance abilities. The BBS includes a 14-item scale with static and dynamic activities of varying difficulty. The overall change in BBS score across 3 years was analyzed at 0, 1, 2, and 3 year visits. Scoring is based on a summation of the 14 item tasks scored on a five-point scale, with a range of 0-4 for each task. 0 = lowest level of function 4 = highest level of function. Highest possible score = 56 A score of \< 45 indicates a greater risk of falling.

Time frame: Baseline up to 36 Months

Population: The number of participants analyzed decreased after baseline at years 1 and 2 as subjects were unable to complete the test. Reasons for not performing a test were missed visits, and refusal to complete task.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in Berg Balance Scale (Full Length) (BBS) ScoreBBS 1Y-6.5 units on a scale
FA ChildrenChange in Berg Balance Scale (Full Length) (BBS) ScoreBBS 2Y-10.4 units on a scale
FA ChildrenChange in Berg Balance Scale (Full Length) (BBS) ScoreBBS 3Y-15 units on a scale
Secondary

Change in FA-Activities of Daily Living Scale (ADL) Score

The Activities of Daily Living (ADL) assesses functional status as a measurement of the participant's ability to perform activities of daily living independently. The ADL comprises 9 questions, each question scored on a scale of 0 to 4, though participants may use increments of 0.5 if they feel they fall between two items. As with the mFARS, the total ADL score is comprised of a summation of each scored question. A minimum value of 0 on the ADL scale indicates self-evaluation of minimal effect for neurological disease components. A maximum score of 36 on the ADL indicates most severe self-evaluation of symptoms included on the survey. The overall change in ADL score across 3 years was analyzed at 0, 1, 2, and 3 year visits.

Time frame: Baseline up to 36 Months

Population: The number of participants analyzed decreased after baseline at years 1, 2, and 3 as subjects were unable to complete the test. Reasons for not performing a test were missed visits, and refusal to complete task.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in FA-Activities of Daily Living Scale (ADL) ScoreADL 1Y0.1 units on a scale
FA ChildrenChange in FA-Activities of Daily Living Scale (ADL) ScoreADL 2Y1.9 units on a scale
FA ChildrenChange in FA-Activities of Daily Living Scale (ADL) ScoreADL 3Y3 units on a scale
Secondary

Change in Timed 25-Foot Walk (T25FW) Test

The timed 25-foot walk (T25FW) test examines gait speed. The participant walks the distance of 25 feet as fast and safe as possible. Participants may use assistive devices during this task. The T25FW test was analyzed at 0, 1, 2, and 3 year visits.

Time frame: Baseline up to 36 Months

Population: Walking tests were carried out in the order: T25FW (twice), 1MW (twice), 6MW, and TUG. The T25FW, was most consistently performed at Baseline. Number of participants analyzed decreased after baseline at year 1, 2, and 3 as subjects were unable to complete the test. Reasons for not performing a test were missed visits, and, if assessment was performed, devices used.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in Timed 25-Foot Walk (T25FW) TestT25FW 1Y-0.2 seconds
FA ChildrenChange in Timed 25-Foot Walk (T25FW) TestT25FW 2Y-0.4 seconds
FA ChildrenChange in Timed 25-Foot Walk (T25FW) TestT25FW 3Y-0.5 seconds
Secondary

Change in Timed Up and Go (TUG) Test

The Timed Up and Go (TUG) test is a timed measure during which the participant has to stand up from a chair, walk 3 meters, turn around, walk back, and sit down. The participant is asked to perform the task as fast and as safe as possible. The TUG is a norm-referenced measure that has established reliability for quickly assessing functional ambulatory mobility and dynamic balance in adults and children. The TUG test was analyzed at 0, 1, 2, and 3 year visits.

Time frame: Baseline up to 36 Months

Population: The TUG was assessed last and was performed by a higher proportion of patients vs. the 6MW. As the difficulty of the tests increased the amount of missing data increased, consistent with the progressive nature of FRDA. The number of participants analyzed decreased after baseline at years 1, 2, and 3 as subjects were unable to complete the test. Possible reasons for not performing a test were collected as fatigue, refused, unable and unable, unrelated to disease progression.

ArmMeasureGroupValue (MEAN)
FA ChildrenChange in Timed Up and Go (TUG) TestTUG*100 1Y-1.4 seconds
FA ChildrenChange in Timed Up and Go (TUG) TestTUG*100 2Y-3.6 seconds
FA ChildrenChange in Timed Up and Go (TUG) TestTUG*100 3Y-4.9 seconds

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026